Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from GoodRx Holdings ( (GDRX) ).
On December 9, 2025, GoodRx Holdings‘ Board of Directors approved retention bonus agreements for CEO Wendy Barnes and CFO Chris McGinnis, offering them cash bonuses of $2 million and $1 million, respectively. These bonuses are contingent upon their continued employment, with repayment conditions if they leave the company under certain circumstances before the end of 2027. The agreements exclude them from participating in the company’s 2025 executive bonus plan or other cash incentive programs for that year.
The most recent analyst rating on (GDRX) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.
Spark’s Take on GDRX Stock
According to Spark, TipRanks’ AI Analyst, GDRX is a Neutral.
GoodRx Holdings shows strong financial performance with improved profitability and cash flow, which is the most significant factor supporting its score. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. The earnings call highlighted both growth opportunities and challenges, balancing the overall outlook.
To see Spark’s full report on GDRX stock, click here.
More about GoodRx Holdings
GoodRx Holdings, Inc. operates in the healthcare industry, primarily focusing on providing prescription drug price comparison services to consumers. The company aims to help individuals access affordable medications by offering discounts and information on drug prices across various pharmacies.
Average Trading Volume: 3,683,308
Technical Sentiment Signal: Sell
Current Market Cap: $947M
For an in-depth examination of GDRX stock, go to TipRanks’ Overview page.